;PMID: 3396004
;source_file_1004.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..199] = [t:44..199]
;2)section:[e:203..250] = [t:203..250]
;3)section:[e:254..365] = [t:254..365]
;4)sentence:[e:369..577] = [t:369..577]
;5)sentence:[e:578..851] = [t:578..851]
;6)sentence:[e:852..991] = [t:852..991]
;7)sentence:[e:992..1139] = [t:992..1139]
;8)sentence:[e:1141..1276] = [t:1141..1276]
;9)sentence:[e:1277..1393] = [t:1277..1393]
;10)sentence:[e:1394..1677] = [t:1394..1677]
;11)sentence:[e:1678..1871] = [t:1678..1871]
;12)sentence:[e:1872..2021] = [t:1872..2021]
;13)sentence:[e:2022..2289] = [t:2022..2289]
;14)section:[e:2293..2337] = [t:2293..2337]

;section 0 Span:0..38
;Cancer Res. 1988 Aug 15;48(16):4513-9.
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..10] Res) (.:[10..11] .) (CD:[12..16] 1988)
        (NNP:[17..20] Aug) (CD:[21..23] 15) (CC:[23..27] ;48-LRB-)
        (CD:[27..29] 16) (-RRB-:[29..30] -RRB-) (CD:[30..35] :4513)
        (::[35..36] -) (CD:[36..38] 9.)))

;sentence 1 Span:44..199
;Specificity of rabbit cytochrome P-450 isozymes involved in the metabolic 
;activation of the food derived mutagen 2-amino-3-methylimidazo[4,5-f]
;quinoline.
;[66..91]:cyp450:"cytochrome P-450 isozymes"
;[137..141]:substance:"food"
;[150..157]:substance:"mutagen"
;[158..198]:substance:"2-amino-3-methylimidazo[4,5-f] quinoline"
(SENT
  (NP-HLN
    (NP (NN:[44..55] Specificity))
    (PP (IN:[56..58] of)
      (NP (NN:[59..65] rabbit)
        
        (NML (NN:[66..76] cytochrome) (NN:[77..82] P-450))
        (NNS:[83..91] isozymes)))
    (VP (VBN:[92..100] involved)
      (NP (-NONE-:[100..100] *))
      (PP-CLR (IN:[101..103] in)
        (NP
          (NP (DT:[104..107] the) (JJ:[108..117] metabolic)
              (NN:[119..129] activation))
          (PP (IN:[130..132] of)
            (NP
              (NP (DT:[133..136] the)
                (ADJP (NN:[137..141] food) (VBN:[142..149] derived))
                (NN:[150..157] mutagen))
              (NP
                  (NN:[158..198] 2-amino-3-methylimidazo-LSB-4,5-f-RSB--SP-quinoline)))))))
    (.:[198..199] .)))

;section 2 Span:203..250
;McManus ME, Burgess W, Snyderwine E, Stupans I.
(SEC
  (FRAG (NNP:[203..210] McManus) (NNP:[211..213] ME) (,:[213..214] ,)
        (NNP:[215..222] Burgess) (NNP:[223..224] W) (,:[224..225] ,)
        (NNP:[226..236] Snyderwine) (NNP:[237..238] E) (,:[238..239] ,)
        (NNP:[240..247] Stupans) (NNP:[248..250] I.)))

;section 3 Span:254..365
;Department of Clinical Pharmacology, School of Medicine, Flinders University
;of  South Australia, Bedford Park.
(SEC
  (FRAG (NNP:[254..264] Department) (IN:[265..267] of) (NNP:[268..276] Clinical)
        (NNP:[277..289] Pharmacology) (,:[289..290] ,) (NNP:[291..297] School)
        (IN:[298..300] of) (NNP:[301..309] Medicine) (,:[309..310] ,)
        (NNP:[311..319] Flinders) (NNP:[320..330] University) (IN:[331..333] of)
        (NNP:[335..340] South) (NNP:[341..350] Australia) (,:[350..351] ,)
        (NNP:[352..359] Bedford) (NNP:[360..364] Park) (.:[364..365] .)))

;sentence 4 Span:369..577
;The involvement of rabbit liver cytochromes P-450 in the activation of the
;food  derived heterocyclic amine mutagen,
;2-amino-3-methylimidazo[4,5-f]quinoline  (IQ), was assessed using the
;Ames/Salmonella test.
;[401..418]:cyp450:"cytochromes P-450"
;[444..448]:substance:"food"
;[458..484]:substance:"heterocyclic amine mutagen"
;[486..525]:substance:"2-amino-3-methylimidazo[4,5-f]quinoline"
;[528..530]:substance:"IQ"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[369..372] The) (NN:[373..384] involvement))
      (PP (IN:[385..387] of)
        (NP (NN:[388..394] rabbit) (NN:[395..400] liver)
           (NNS:[401..412] cytochromes) (NN:[413..418] P-450)))
      (PP (IN:[419..421] in)
        (NP
          (NP (DT:[422..425] the) (NN:[426..436] activation))
          (PP (IN:[437..439] of)
            (NP
              (NP (DT:[440..443] the)
                (ADJP (NN:[444..448] food) (VBN:[450..457] derived))
                 (JJ:[458..470] heterocyclic) (NN:[471..476] amine)
                 (NN:[477..484] mutagen))
              (,:[484..485] ,)
              (NP
                (NP
                    (NN:[486..525] 2-amino-3-methylimidazo-LSB-4,5-f-RSB-quinoline))
                (NP (-LRB-:[527..528] -LRB-) (NN:[528..530] IQ)
                    (-RRB-:[530..531] -RRB-))))))))
    (,:[531..532] ,)
    (VP (VBD:[533..536] was)
      (VP (VBN:[537..545] assessed)
        (NP-1 (-NONE-:[545..545] *))
        (S-MNR
          (NP-SBJ (-NONE-:[545..545] *))
          (VP (VBG:[546..551] using)
            (NP (DT:[552..555] the)
              (NML (NNP:[556..560] Ames) (SYM:[560..561] /)
                   (NNP:[561..571] Salmonella))
              (NN:[572..576] test))))))
    (.:[576..577] .)))

;sentence 5 Span:578..851
;The number of revertants  induced by IQ per microgram of control rabbit liver
;microsomes was 1872 +/- 50  (SD, n = 3), and this increased to 3690 +/- 239
;when microsomes from  2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) animals were
;used as the metabolic  activation source.
;[615..617]:substance:"IQ"
;[671..682]:quantitative-value:"1872 +/- 50"
;[719..731]:quantitative-value:"3690 +/- 239"
;[754..789]:substance:"2,3,7,8-tetrachlorodibenzo-p-dioxin"
;[791..795]:substance:"TCDD"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[578..581] The) (NN:[582..588] number))
        (PP (IN:[589..591] of)
          (NP
            (NP (NNS:[592..602] revertants))
            (VP (VBN:[604..611] induced)
              (NP (-NONE-:[611..611] *))
              (PP (IN:[612..614] by)
                (NP-LGS (NN:[615..617] IQ))))))
        (PP (IN:[618..621] per)
          (NP
            (NP (NN:[622..631] microgram))
            (PP (IN:[632..634] of)
              (NP (NN:[635..642] control) (NN:[643..649] rabbit)
                  (NN:[650..655] liver) (NNS:[656..666] microsomes))))))
      (VP (VBD:[667..670] was)
        (NP-PRD
          (QP (CD:[671..675] 1872) (SYM:[676..679] +/-) (CD:[680..682] 50))
          (PRN (-LRB-:[684..685] -LRB-)
            (FRAG
              (NP (NN:[685..687] SD))
              (,:[687..688] ,)
              (S
                (NP-SBJ (NN:[689..690] n))
                (VP (SYM:[691..692] =)
                  (NP (CD:[693..694] 3)))))
            (-RRB-:[694..695] -RRB-)))))
    (,:[695..696] ,) (CC:[697..700] and)
    (S
      (NP-SBJ (DT:[701..705] this))
      (VP (VBD:[706..715] increased)
        (PP (TO:[716..718] to)
          (NP
            (QP (CD:[719..723] 3690) (SYM:[724..727] +/-) (CD:[728..731] 239))))
        (SBAR-ADV
          (WHADVP-2 (WRB:[732..736] when))
          (S
            (NP-SBJ-1
              (NP (NNS:[737..747] microsomes))
              (PP (IN:[748..752] from)
                (NP
                  (NML
                    (NML (NN:[754..789] 2,3,7,8-tetrachlorodibenzo-p-dioxin))
                    (NML (-LRB-:[790..791] -LRB-) (NN:[791..795] TCDD)
                         (-RRB-:[795..796] -RRB-)))
                  (NNS:[797..804] animals))))
            (VP (VBD:[805..809] were)
              (VP (VBN:[810..814] used)
                (NP-1 (-NONE-:[814..814] *))
                (PP (IN:[815..817] as)
                  (NP (DT:[818..821] the) (JJ:[822..831] metabolic)
                      (NN:[833..843] activation) (NN:[844..850] source)))
                (ADVP-TMP-2 (-NONE-:[850..850] *T*))))))))
    (.:[850..851] .)))

;sentence 6 Span:852..991
;Microsomes from phenobarbital, rifampicin, and acetone  pretreated rabbits
;were less efficient the controls at activating IQ to a  mutagen.
;[868..881]:substance:"phenobarbital"
;[883..893]:substance:"rifampicin"
;[899..906]:substance:"acetone"
;[974..976]:substance:"IQ"
;[983..990]:substance:"mutagen"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[852..862] Microsomes))
      (PP (IN:[863..867] from)
        (NP
          (NP
            (ADJP (NN:[868..881] phenobarbital)
              (ADJP-1 (-NONE-:[881..881] *P*)))
            (NML-2 (-NONE-:[881..881] *P*)))
          (,:[881..882] ,)
          (NP
            (ADJP (NN:[883..893] rifampicin)
              (ADJP-1 (-NONE-:[893..893] *P*)))
            (NML-2 (-NONE-:[893..893] *P*)))
          (,:[893..894] ,) (CC:[895..898] and)
          (NP
            (ADJP (NN:[899..906] acetone)
              (ADJP-1 (VBN:[908..918] pretreated)))
            (NML-2 (NNS:[919..926] rabbits))))))
    (VP (VBD:[927..931] were)
      (ADJP-PRD
        (ADJP (RBR:[932..936] less) (JJ:[937..946] efficient))
        (FRAG
          (NP (IN:[947..950] the) (NNS:[951..959] controls)))
        (PP (IN:[960..962] at)
          (S-NOM
            (NP-SBJ (-NONE-:[962..962] *))
            (VP (VBG:[963..973] activating)
              (NP (NN:[974..976] IQ))
              (PP (TO:[977..979] to)
                (NP (DT:[980..981] a) (NN:[983..990] mutagen))))))))
    (.:[990..991] .)))

;sentence 7 Span:992..1139
;Cytochrome P-450 Forms 4 and 6, which are induced by TCDD, were found  to be
;efficient activators of IQ to a mutagen in reconstitution experiments.
;[992..1016]:cyp450:"Cytochrome P-450 Forms 4"
;[992..1014]...[1021..1022]:cyp450:"Cytochrome P-450 Forms"..."6"
;[1045..1049]:substance:"TCDD"
;[1079..1089]:substance:"activators"
;[1093..1095]:substance:"IQ"
;[1101..1108]:substance:"mutagen"
(SENT
  (S
    (NP-SBJ-4
      (NP
        (NP
          (NML-3 (NN:[992..1002] Cytochrome) (NN:[1003..1008] P-450))
          (NML-2 (NNS:[1009..1014] Forms))
          (CD:[1015..1016] 4))
        (CC:[1017..1020] and)
        (NP
          (NML-3 (-NONE-:[1020..1020] *P*))
          (NML-2 (-NONE-:[1020..1020] *P*))
          (CD:[1021..1022] 6)))
      (,:[1022..1023] ,)
      (SBAR
        (WHNP-1 (WDT:[1024..1029] which))
        (S
          (NP-SBJ-1 (-NONE-:[1029..1029] *T*))
          (VP (VBP:[1030..1033] are)
            (VP (VBN:[1034..1041] induced)
              (NP-1 (-NONE-:[1041..1041] *))
              (PP (IN:[1042..1044] by)
                (NP-LGS (NN:[1045..1049] TCDD))))))))
    (,:[1049..1050] ,)
    (VP (VBD:[1051..1055] were)
      (VP (VBN:[1056..1061] found)
        (S
          (NP-SBJ-4 (-NONE-:[1061..1061] *))
          (VP (TO:[1063..1065] to)
            (VP (VB:[1066..1068] be)
              (NP-PRD
                (NP (JJ:[1069..1078] efficient) (NNS:[1079..1089] activators))
                (PP (IN:[1090..1092] of)
                  (NP (NN:[1093..1095] IQ)))
                (PP (TO:[1096..1098] to)
                  (NP (DT:[1099..1100] a) (NN:[1101..1108] mutagen))))
              (PP (IN:[1109..1111] in)
                (NP (NN:[1112..1126] reconstitution)
                    (NNS:[1127..1138] experiments))))))))
    (.:[1138..1139] .)))

;sentence 8 Span:1141..1276
;Form 4 was 7.7-fold more active than Form 6 and produced 1702
;revertants/0.125  pmol with a 20-min preincubation step in the Ames test.
;[1141..1147]:cyp450:"Form 4"
;[1152..1160]:quantitative-value:"7.7-fold"
;[1178..1184]:cyp450:"Form 6"
;[1198..1202]:quantitative-value:"1702"
;[1214..1219]:quantitative-value:"0.125"
;[1221..1225]:quantitative-units:"pmol"
;[1233..1235]:quantitative-value:"20"
;[1236..1239]:quantitative-units:"min"
(SENT
  (S
    (NP-SBJ (NN:[1141..1145] Form) (CD:[1146..1147] 4))
    (VP
      (VP (VBD:[1148..1151] was)
        (ADJP-PRD
          (ADJP
            (QP (CD:[1152..1155] 7.7) (HYPH:[1155..1156] -)
                (RB:[1156..1160] fold))
            (RBR:[1161..1165] more) (JJ:[1166..1172] active))
          (PP (IN:[1173..1177] than)
            (NP (NN:[1178..1182] Form) (CD:[1183..1184] 6)))))
      (CC:[1185..1188] and)
      (VP (VBD:[1189..1197] produced)
        (NP
          (NP (CD:[1198..1202] 1702) (NNS:[1203..1213] revertants))
          (PP (SYM:[1213..1214] /)
            (NP (CD:[1214..1219] 0.125) (NN:[1221..1225] pmol))))
        (PP (IN:[1226..1230] with)
          (NP
            (NP (DT:[1231..1232] a)
              (NML (CD:[1233..1235] 20) (HYPH:[1235..1236] -)
                   (NN:[1236..1239] min))
              (NN:[1240..1253] preincubation) (NN:[1254..1258] step))
            (PP (IN:[1259..1261] in)
              (NP (DT:[1262..1265] the) (NNP:[1266..1270] Ames)
                  (NN:[1271..1275] test)))))))
    (.:[1275..1276] .)))

;sentence 9 Span:1277..1393
;Anti-Form 4 IgG  inhibited the activation of IQ in control and TCDD induced
;microsomes by 78 and  79%, respectively.
;[1277..1292]:substance:"Anti-Form 4 IgG"
;[1322..1324]:substance:"IQ"
;[1340..1344]:substance:"TCDD"
;[1367..1369]...[1377..1378]:quantitative-value:"78"..."%"
;[1375..1378]:quantitative-value:"79%"
(SENT
  (S
    (NP-SBJ
      (NML (AFX:[1277..1281] Anti) (HYPH:[1281..1282] -) (NN:[1282..1286] Form)
           (CD:[1287..1288] 4))
      (NN:[1289..1292] IgG))
    (VP (VBD:[1294..1303] inhibited)
      (NP
        (NP (DT:[1304..1307] the) (NN:[1308..1318] activation))
        (PP (IN:[1319..1321] of)
          (NP (NN:[1322..1324] IQ))))
      (PP-LOC (IN:[1325..1327] in)
        (NP
          (NP (NN:[1328..1335] control)
            (NML-1 (-NONE-:[1335..1335] *P*)))
          (CC:[1336..1339] and)
          (NP
            (ADJP (NN:[1340..1344] TCDD) (VBN:[1345..1352] induced))
            (NML-1 (NNS:[1353..1363] microsomes)))))
      (PP-EXT (IN:[1364..1366] by)
        (NP
          (NP (CD:[1367..1369] 78)
            (NML-2 (-NONE-:[1369..1369] *P*)))
          (CC:[1370..1373] and)
          (NP (CD:[1375..1377] 79)
            (NML-2 (NN:[1377..1378] %)))))
      (,:[1378..1379] ,)
      (ADVP (RB:[1380..1392] respectively)))
    (.:[1392..1393] .)))

;sentence 10 Span:1394..1677
;The contents of cytochrome P-450 Form 4, determined by  Western blot
;analysis, in control and phenobarbital, acetone, rifampicin, and  TCDD
;pretreated microsomes were 0.55 +/- 0.19, 0.63 +/- 0.34, 0.5 +/- 0.27, 0.28 
;+/- 0.16, and 2.19 +/- 0.43 (n = 3) nmol/mg protein, respectively.
;[1410..1433]:cyp450:"cytochrome P-450 Form 4"
;[1488..1501]:substance:"phenobarbital"
;[1503..1510]:substance:"acetone"
;[1512..1522]:substance:"rifampicin"
;[1529..1533]:substance:"TCDD"
;[1561..1574]:quantitative-value:"0.55 +/- 0.19"
;[1576..1589]:quantitative-value:"0.63 +/- 0.34"
;[1591..1603]:quantitative-value:"0.5 +/- 0.27"
;[1605..1619]:quantitative-value:"0.28  +/- 0.16"
;[1625..1638]:quantitative-value:"2.19 +/- 0.43"
;[1647..1662]:quantitative-units:"nmol/mg protein"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[1394..1397] The) (NNS:[1398..1406] contents))
        (PP (IN:[1407..1409] of)
          (NP
            (NP (NN:[1410..1420] cytochrome) (NN:[1421..1426] P-450))
            (NN:[1427..1431] Form) (CD:[1432..1433] 4))))
      (,:[1433..1434] ,)
      (VP (VBN:[1435..1445] determined)
        (NP (-NONE-:[1445..1445] *))
        (PP-MNR (IN:[1446..1448] by)
          (NP
            (NML (NNP:[1450..1457] Western) (NN:[1458..1462] blot))
            (NN:[1463..1471] analysis))))
      (,:[1471..1472] ,)
      (PP-LOC (IN:[1473..1475] in)
        (NP
          (NP (NN:[1476..1483] control)
            (NML-3 (-NONE-:[1483..1483] *P*)))
          (CC:[1484..1487] and)
          (NP
            (NP
              (ADJP (NN:[1488..1501] phenobarbital)
                (ADJP-2 (-NONE-:[1501..1501] *P*)))
              (NML-3 (-NONE-:[1501..1501] *P*)))
            (,:[1501..1502] ,)
            (NP
              (ADJP (NN:[1503..1510] acetone)
                (ADJP-2 (-NONE-:[1510..1510] *P*)))
              (NML-3 (-NONE-:[1510..1510] *P*)))
            (,:[1510..1511] ,)
            (NP
              (ADJP (NN:[1512..1522] rifampicin)
                (ADJP-2 (-NONE-:[1522..1522] *P*)))
              (NML-3 (-NONE-:[1522..1522] *P*)))
            (,:[1522..1523] ,) (CC:[1524..1527] and)
            (NP
              (ADJP (NN:[1529..1533] TCDD)
                (ADJP-2 (VBN:[1534..1544] pretreated)))
              (NML-3 (NNS:[1545..1555] microsomes)))))))
    (VP (VBD:[1556..1560] were)
      (NP-PRD
        (NP
          (NP
            (QP (CD:[1561..1565] 0.55) (SYM:[1566..1569] +/-)
                (CD:[1570..1574] 0.19))
            (NML-1 (-NONE-:[1574..1574] *P*)))
          (,:[1574..1575] ,)
          (NP
            (QP (CD:[1576..1580] 0.63) (SYM:[1581..1584] +/-)
                (CD:[1585..1589] 0.34))
            (NML-1 (-NONE-:[1589..1589] *P*)))
          (,:[1589..1590] ,)
          (NP
            (QP (CD:[1591..1594] 0.5) (SYM:[1595..1598] +/-)
                (CD:[1599..1603] 0.27))
            (NML-1 (-NONE-:[1603..1603] *P*)))
          (,:[1603..1604] ,)
          (NP
            (QP (CD:[1605..1609] 0.28) (SYM:[1611..1614] +/-)
                (CD:[1615..1619] 0.16))
            (NML-1 (-NONE-:[1619..1619] *P*)))
          (,:[1619..1620] ,) (CC:[1621..1624] and)
          (NP
            (QP (CD:[1625..1629] 2.19) (SYM:[1630..1633] +/-)
                (CD:[1634..1638] 0.43))
            (PRN (-LRB-:[1639..1640] -LRB-)
              (S
                (NP-SBJ (NN:[1640..1641] n))
                (VP (SYM:[1642..1643] =)
                  (NP (CD:[1644..1645] 3))))
              (-RRB-:[1645..1646] -RRB-))
            (NML-1 (NN:[1647..1651] nmol))))
        (PP (SYM:[1651..1652] /)
          (NP (NN:[1652..1654] mg) (NN:[1655..1662] protein))))
      (,:[1662..1663] ,)
      (ADVP (RB:[1664..1676] respectively)))
    (.:[1676..1677] .)))

;sentence 11 Span:1678..1871
;A highly  significant statistical correlation existed between the capacity of
;the above  microsomes to activate IQ to a mutagen and their cytochrome P-450
;Form 4 content  (r = 0.96; r2 = 0.92).
;[1790..1792]:substance:"IQ"
;[1798..1805]:substance:"mutagen"
;[1816..1839]:cyp450:"cytochrome P-450 Form 4"
(SENT
  (S
    (NP-SBJ (DT:[1678..1679] A)
      (ADJP (RB:[1680..1686] highly) (JJ:[1688..1699] significant))
      (JJ:[1700..1711] statistical) (NN:[1712..1723] correlation))
    (VP (VBD:[1724..1731] existed)
      (PP (IN:[1732..1739] between)
        (NP
          (NP
            (NP (DT:[1740..1743] the) (NN:[1744..1752] capacity)
              (S-1 (-NONE-:[1752..1752] *ICH*)))
            (PP (IN:[1753..1755] of)
              (NP (DT:[1756..1759] the) (JJ:[1760..1765] above)
                  (NNS:[1767..1777] microsomes)))
            (S-1
              (NP-SBJ (-NONE-:[1777..1777] *))
              (VP (TO:[1778..1780] to)
                (VP (VB:[1781..1789] activate)
                  (NP (NN:[1790..1792] IQ))
                  (PP (TO:[1793..1795] to)
                    (NP (DT:[1796..1797] a) (NN:[1798..1805] mutagen)))))))
          (CC:[1806..1809] and)
          (NP (PRP$:[1810..1815] their)
            
            (NML (NN:[1816..1826] cytochrome) (NN:[1827..1832] P-450))
            (NML (NN:[1833..1837] Form) (CD:[1838..1839] 4))
            (NN:[1840..1847] content))
          (PRN (-LRB-:[1849..1850] -LRB-)
            (S
              (S
                (NP-SBJ (NN:[1850..1851] r))
                (VP (SYM:[1852..1853] =)
                  (NP (CD:[1854..1858] 0.96))))
              (::[1858..1859] ;)
              (S
                (NP-SBJ (NN:[1860..1862] r2))
                (VP (SYM:[1863..1864] =)
                  (NP (CD:[1865..1869] 0.92)))))
            (-RRB-:[1869..1870] -RRB-)))))
    (.:[1870..1871] .)))

;sentence 12 Span:1872..2021
;The content of cytochrome P-450 Form 6 in the above  microsomes was also
;highly correlated with their capacity to activate IQ (r =  0.92; r2 = 0.85).
;[1887..1910]:cyp450:"cytochrome P-450 Form 6"
;[1995..1997]:substance:"IQ"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1872..1875] The) (NN:[1876..1883] content))
      (PP (IN:[1884..1886] of)
        (NP
          (NML (NN:[1887..1897] cytochrome) (NN:[1898..1903] P-450))
          (NN:[1904..1908] Form) (CD:[1909..1910] 6)))
      (PP-LOC (IN:[1911..1913] in)
        (NP (DT:[1914..1917] the) (JJ:[1918..1923] above)
            (NNS:[1925..1935] microsomes))))
    (VP (VBD:[1936..1939] was)
      (ADVP (RB:[1940..1944] also))
      (ADVP (RB:[1945..1951] highly))
      (VP (VBN:[1952..1962] correlated)
        (NP-1 (-NONE-:[1962..1962] *))
        (PP-CLR (IN:[1963..1967] with)
          (NP (PRP$:[1968..1973] their) (NN:[1974..1982] capacity)
            (S
              (NP-SBJ (-NONE-:[1982..1982] *))
              (VP (TO:[1983..1985] to)
                (NP (VB:[1986..1994] activate) (NN:[1995..1997] IQ))))))
        (PRN (-LRB-:[1998..1999] -LRB-)
          (S
            (S
              (NP-SBJ (NN:[1999..2000] r))
              (VP (SYM:[2001..2002] =)
                (NP (CD:[2004..2008] 0.92))))
            (::[2008..2009] ;)
            (S
              (NP-SBJ (NN:[2010..2012] r2))
              (VP (SYM:[2013..2014] =)
                (NP (CD:[2015..2019] 0.85)))))
          (-RRB-:[2019..2020] -RRB-))))
    (.:[2020..2021] .)))

;sentence 13 Span:2022..2289
;Based on these results and the tissue distribution of  cytochrome P-450 Forms
;4 and 6, the former obviously contributes most toward the  activation of IQ
;in the liver, whereas Form 6 would be expected to be primarily  involved in
;this process in extrahepatic tissues.
;[2077..2101]:cyp450:"cytochrome P-450 Forms 4"
;[2077..2099]...[2106..2107]:cyp450:"cytochrome P-450 Forms"..."6"
;[2173..2175]:substance:"IQ"
;[2198..2204]:cyp450:"Form 6"
(SENT
  (S
    (S-ADV
      (NP-SBJ-3 (-NONE-:[2022..2022] *))
      (VP (VBN:[2022..2027] Based)
        (NP-3 (-NONE-:[2027..2027] *))
        (PP-CLR (IN:[2028..2030] on)
          (NP
            (NP (DT:[2031..2036] these) (NNS:[2037..2044] results))
            (CC:[2045..2048] and)
            (NP
              (NP (DT:[2049..2052] the) (NN:[2053..2059] tissue)
                  (NN:[2060..2072] distribution))
              (PP (IN:[2073..2075] of)
                (NP
                  (NP
                    (NML-2 (NN:[2077..2087] cytochrome) (NN:[2088..2093] P-450))
                    (NML-1 (NNS:[2094..2099] Forms))
                    (CD:[2100..2101] 4))
                  (CC:[2102..2105] and)
                  (NP
                    (NML-2 (-NONE-:[2105..2105] *P*))
                    (NML-1 (-NONE-:[2105..2105] *P*))
                    (CD:[2106..2107] 6)))))))))
    (,:[2107..2108] ,)
    (NP-SBJ (DT:[2109..2112] the) (JJ:[2113..2119] former))
    (ADVP (RB:[2120..2129] obviously))
    (VP (VBZ:[2130..2141] contributes)
      (NP (RBS:[2142..2146] most))
      (PP (IN:[2147..2153] toward)
        (NP
          (NP (DT:[2154..2157] the) (NN:[2159..2169] activation))
          (PP (IN:[2170..2172] of)
            (NP (NN:[2173..2175] IQ)))
          (PP-LOC (IN:[2176..2178] in)
            (NP (DT:[2179..2182] the) (NN:[2183..2188] liver)))))
      (,:[2188..2189] ,)
      (SBAR-ADV (IN:[2190..2197] whereas)
        (S
          (NP-SBJ-4 (NN:[2198..2202] Form) (CD:[2203..2204] 6))
          (VP (MD:[2205..2210] would)
            (VP (VB:[2211..2213] be)
              (VP (VBN:[2214..2222] expected)
                (S
                  (NP-SBJ-4 (-NONE-:[2222..2222] *))
                  (VP (TO:[2223..2225] to)
                    (VP (VB:[2226..2228] be)
                      (ADVP (RB:[2229..2238] primarily))
                      (VP (VBN:[2240..2248] involved)
                        (NP-4 (-NONE-:[2248..2248] *))
                        (PP-CLR (IN:[2249..2251] in)
                          (NP (DT:[2252..2256] this) (NN:[2257..2264] process)))
                        (PP-LOC (IN:[2265..2267] in)
                          (NP (JJ:[2268..2280] extrahepatic)
                              (NNS:[2281..2288] tissues)))))))))))))
    (.:[2288..2289] .)))

;section 14 Span:2293..2337
;PMID: 3396004 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2293..2297] PMID) (::[2297..2298] :) (CD:[2299..2306] 3396004)
        (NN:[2307..2308] -LSB-) (NNP:[2308..2314] PubMed) (::[2315..2316] -)
        (NN:[2317..2324] indexed) (IN:[2325..2328] for)
        (NNP:[2329..2337] MEDLINE-RSB-)))
